Clinical trial
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in…
NCT00129831 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00129831 |
|---|---|
| Title | Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | Dose Escalation Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | COPD |
| Intervention type | Drug |
| Interventions | QAB149 |
| Enrollment | 6 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Aug 12, 2005 |
| Last update posted | Oct 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: